DuPont announced the expansion of its ion exchange resin manufacturing production to address the high global demand for its pharmaceutical products such as excipients and active pharmaceutical ingredients (APIs).
To support their pharmaceutical customers’ growth and needs for cGMP qualified products, DuPont is expanding its ability to manufacture and supply these critical products, according to the Dupont press release. With the additions of a few key technologies to its production operations, these investments aim to enhance security of supply for improving present and future drug formulations.
The production expansion will be in phases, according to the press release. The first phase is to increase capacity of DuPont’s dedicated cGMP pharmaceutical production units in Chauny, France, and is complete with qualifications underway. Future phases will focus on increased supply of highly demanded excipient and absorbent products, and are expected in the coming years.
“When our customers select one of our products, they count on us to supply not just what they need today, but what they need for the lifetime of their products,” said Condylia Courtney, global product line manager for Ion Exchange Resins at Dupont in the press release. “This investment demonstrates our commitment to growing with our customers and ensuring supply of their critical excipients.”
Along with the production expansion, DuPont is also increasing regulatory resources. The expanded regulatory team will continue to work with technical experts to develop new applications, launch new products, and work to guarantee best product quality and performance across various markets.
